10 Amendments of Aldo PATRICIELLO related to 2022/2008(INI)
Amendment 34 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas the European Commission, after identifying its strategic dependencies in the most sensitive industrial ecosystems, such as health, will propose concrete systemic (economic and regulatory) measures to reduce these dependencies, including by securing and fostering production and investment in Europe to ensure patients access and health care system sustainability;
Amendment 47 #
Motion for a resolution
Recital C b (new)
Recital C b (new)
Cb. whereas the European Commission has recognised the health industrial ecosystem, including active pharmaceutical ingredients and other health related products such as essential medicines, as vital to achieve its open strategic autonomy;
Amendment 49 #
Motion for a resolution
Recital C c (new)
Recital C c (new)
Cc. whereas the European Commission has recognised in the new updated industrial strategy that unsustainable market policies, included on public procurement, could lead to market consolidation, and in the health sector this is one of the main drivers of medicine shortages;
Amendment 54 #
Motion for a resolution
Recital C d (new)
Recital C d (new)
Cd. whereas the European Commission has recognised in the new updated industrial strategy that unsustainable market policies, included on public procurement, could lead to market consolidation, increasing the risk of medicines shortage;
Amendment 168 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Welcomes the Commission’s announcement issuing guidance on public procurement; stresses that public procurement is an essential instrument for national and economic security and for supporting the uptake of and demand for clean products; calls, in this regard, on the Commission to review public procurement and competition rules where needed;
Amendment 171 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Recalls the role of sustainable procurement practices in preventing medicine shortage ensuring security of supply and securing manufacturing investments; as recognised in the updated new industrial strategy in the context of the health ecosystem, public procurement can lead to market consolidation and increases the risk of shortages. Urges the Commission, to support Member States by developing targeted EU rules on medicines procurement, under the current public procurement directive, aimed at ensuring long-term sustainability, competition, security of supply and stimulating investments in manufacturing. These guidelines or legislative changes in the pharmaceutical legislation should cover clarification and recommendations to Member States on how to apply the Most Economic Advantageous Tender (MEAT) criteria, ensure timely procurement processes to ensure the plurality of manufacturers and competition of multisource medicines as soon as they are available;
Amendment 181 #
Motion for a resolution
Paragraph 7 b (new)
Paragraph 7 b (new)
7b. Calls on the Commission to assess the joint procurements launched during the Covid-19 outbreak, to compare them with the advanced purchased agreement, and take the lesson learned to improve this tool by avoiding any internal market disruption. Joint Procurement should have no impact on pre-existing contractual agreements with suppliers and should be carried out in accordance with the Directive 2014/24/EU in a transparent manner, while respecting the following conditions: procurement process, criteria, timelines, specifications and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;
Amendment 286 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14a. Calls on the Commission, to propose incentives to stimulate investments in production of critical goods as well as manufacturing technology (greening, digital, process technology, automation), such as off- patent medicines. Those investments are needed to enable European manufacturers to upgrade their production technology to remain globally competitive and to meet societal expectations for supply security and promote talent retention to achieve the goals of the next Generation EU, especially in the fourteen identified ecosystems;
Amendment 292 #
Motion for a resolution
Paragraph 14 b (new)
Paragraph 14 b (new)
14b. Urgently calls on the Commission and Member States to create ad hoc incentives for the production of critical goods, such as essential medicines, to achieve its open strategic autonomy in view of any kind of crisis, including a war, while ensuring long term resilient supply chains. This can be achieved via a special temporary state aid framework either by enlarging the health IPCEI framework to include access to funds for essential medicines production, as well as via establishing dedicated funds under HERA, or any other compatible EU fund;
Amendment 295 #
Motion for a resolution
Paragraph 14 c (new)
Paragraph 14 c (new)
14c. Urgently calls on the Commission and Member States to create incentives to support industrial sectors that are facing the sharp increase of energy, transport and raw materials costs, which are exacerbated by the current conflict in Ukraine. These aids should be particularly addressed to strategic sectors, such as the pharmaceutical one to ensure the supply of affordable medicines;